KLAC vs STRO · P/E 55, rev $12.16B vs rev $62.0M
KLA Corporation (KLAC) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported KLAC revenue for 2025-06-30 was $12.16B. Net income was $4.06B. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
KLAC currently screens at market cap $252.01B and trailing P/E 54.7. STRO currently screens at market cap $470.8M.
Not investment advice. Open the KLAC and STRO stock pages for the full models.
Not investment advice.